The highest-paying job in California is ophthalmologist - $347,000 a year on average. That figure isn't a rounding error. It's a demand signal. People are spending enormous sums to see better, and the companies that sell the surgical instruments, lenses, and devices behind those procedures are the real economic winners hiding inside a career salary article.
The largest publicly traded player in that ecosystem is Alcon (ALC). It's the one-stop shop for cataract surgery consumables, surgical equipment, and vision care products. An Alcon intraocular lens gets implanted somewhere in the world every four seconds, which is a way of saying the distribution is locked and the recurring revenue model works. Surgeons don't switch suppliers lightly.
Here's what the numbers show right now. Alcon delivered 2025 net sales of $10.3 billion, up 5%. But the acceleration is in the back half - fourth-quarter sales jumped 9%, and Q1 2026 came in at $2.7 billion, up 6%. The surgical franchise brought in $1.5 billion that quarter. Free cash flow for the year was over $1.2 billion. That's not noise. That's a business where the pipeline is actually turning into cash.
The demand mechanics are structural. The cataract surgery devices market is projected to expand from $9.25 billion in 2025 to $12.47 billion by 2033. The presbyopia treatment market - aging-related vision correction - sits at $11 billion and is growing at 4.6% to 8.5% depending on the model. Over-50 demographics in the U.S. and globally are not going to reverse. This is not a fad. It's a plumbing issue: more old eyes, more procedures, more consumables.
So the story is real. Where it gets uncomfortable is the price. Alcon trades at roughly 40 times trailing earnings, with a PEG ratio - the P/E divided by the earnings growth rate, a rough gauge of whether you're paying too much for the growth you're getting - of nearly 10. That means the market is charging you 10 times more for each percent of earnings growth than the baseline definition of "fair." On a $33 billion market cap, the stock has already absorbed a lot of this tailwind.
I'm not saying the business is wrong. I'm saying the entry is wrong. At 40x earnings for 5% to 9% revenue growth, the stock demands flawless execution and margin expansion just to hold its multiple. The return on equity sits at 4.5%, which is low for a company with this kind of franchise pricing power. That gap between the valuation and the profitability is what makes me want to stand on the sidelines.
The old story around Alcon was that it would struggle after spinning off from Novartis - loss of scale, loss of R&D depth, loss of the Novartis balance sheet. The market has moved past that fear. But now it's moved too far in the other direction. It's pricing perfection for a business that is still building itself.
This is where discipline over ego matters. The setup is clean on the demand side. The cash flow is real. But the multiple is doing too much heavy lifting. I'd wait for the stock to pull back into a range where the P/E compresses below 30x - or for earnings to grow fast enough to justify the current price. Until then, the $347K salary signal and the Alcon valuation are telling different stories.
What would change my mind? Two things. Alcon sustains quarter-over-quarter growth at 8% or above for two consecutive quarters, which proves the Q4 acceleration wasn't a one-off bump. Or the stock corrects to the low $60s or below, where the P/E would fall into a zone where the cash flow alone makes the position defensible even if growth slows.
What would prove me wrong and make this a missed entry? If the presbyopia pipeline or the premium lens portfolio drives unexpected operating leverage, pushing free cash flow margins above 15% while revenue stays in the low double digits. That rerates the whole math. But at current levels, I'd rather be early and patient than expensive and hopeful.
Discipline over ego. Sit on your hands.